The research in our laboratories is concentrated on deriving information related to the clinical pharmacology of anticancer agents.  To accomplish our research objectives, we establish suitable analytical (HPLC, CE, LC/MS) or molecular (PCR, Western, Elisa) methods for the measurement of the compounds in biological fluids or tissue.  We explore the relationships between the pharmacokinetic parameters (clearance, AUC) of the agent and their biological targets, activity and/or toxicity.  These correlations permit the development of rational dosing and scheduling regimens for the optimization of the compound's therapeutic index.     We also evaluate genetic variations responsible for drug metabolism, transport or target affinity.  The laboratories serve as the Pharmacology Core for the North American Brain Tumor Consortium (NABTC).